HIV integrase inhibitors

US8129398B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Francis Beaulieu · Elliot Lake, CA
• Carl Ouellet · Boucherville, CA
• B. Narasimhulu Naidu · Durham, US
• Manoj Patel · Berlin, US
• Yasutsugu Ueda · Clinton, US
• Timothy P. Connolly · Portland, US
• Jonathan R. Weiss · Boston, US
• Michael A. Walker · Durham, US
• Nicholas A. Meanwell · East Hampton, US
• Kevin Peese · Haddam, US
• Margaret E. Sorenson · Swedesburg, US
• Chen Li · South Glastonbury, US

Key dates

• Filing date: Mar 18, 2009
• Grant date: Mar 6, 2012
• Expiry date: May 21, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D493/18
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.